| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Outstanding accounts and tenants receivable | | | | 0.9 | 0.5 | | | |
| C | | | | 0.3 | | | | |
| Medical related consulting services - related parties | | | | 0.3 | | | | |
| Other | | | | 0.1 | 0.6 | | | |
| Total revenues [+] | 1.4 | 1.4 | 1.5 | 1.6 | 1.1 | 0.6 | 0.0 | 0.0 |
| Technology services | | | | | | 0.6 | | |
| Other income | | | | | | 0.0 | | |
| Revenue growth [+] | 1.0% | -10.9% | -1.0% | 45.0% | 74.8% | | | |
| Outstanding accounts and tenants receivable | | | | 66.0% | | | | |
| Cost of goods sold | 1.0 | 1.0 | 1.2 | 1.2 | 1.1 | 0.1 | 0.0 | 0.0 |
| Gross profit | 0.4 | 0.4 | 0.3 | 0.4 | 0.0 | 0.5 | 0.0 | 0.0 |
| Gross margin | 29.8% | 28.3% | 22.0% | 24.8% | -4.6% | 88.1% | | |
| Selling, general and administrative [+] | 8.2 | 12.0 | 16.9 | 8.0 | 2.8 | 0.5 | 0.0 | 0.0 |
| Sales and marketing | | | | | 0.0 | 0.0 | | |
| General and administrative [+] | 8.2 | 12.0 | 16.9 | 8.0 | 2.8 | 0.4 | 0.0 | 0.0 |
| Wages and related expenses | 2.0 | 4.2 | 8.7 | 2.7 | 1.3 | 0.0 | | |
| General and administrative expenses | | | | | 2.8 | 0.4 | 0.0 | 0.0 |
| Professional fees | 4.9 | 6.6 | 6.0 | | 1.0 | 0.4 | | |
| Other selling, general and administrative | | | | | | 0.0 | | |
| Research and development | 1.0 | 0.9 | 1.8 | 0.0 | | | | |
| Equity in earnings | 0.1 | 0.1 | -0.1 | -0.1 | | | | |
| Other operating expenses | | -0.9 | 1.0 | | -0.3 | | | |
| EBITDA [+] | -8.5 | -11.2 | -18.9 | -7.2 | -2.4 | 0.1 | | |
| EBITDA growth | -24.4% | -40.9% | 164.3% | 201.5% | -3185.9% | -348.2% | 785.9% | |
| EBITDA margin | -608.3% | -812.0% | -1224.0% | -458.4% | -220.4% | 12.5% | | |
| Depreciation | 0.3 | 0.3 | 0.5 | 0.2 | 0.2 | 0.0 | | |
| EBITA | -8.8 | -11.5 | -19.4 | -7.4 | -2.6 | 0.1 | 0.0 | 0.0 |
| EBITA margin | -630.7% | -834.9% | -1256.7% | -470.9% | -237.3% | 12.5% | | |
| Amortization of intangibles | | | | 0.3 | | | | |
| EBIT [+] | -8.8 | -11.5 | -19.4 | -7.7 | -2.6 | 0.1 | 0.0 | 0.0 |
| EBIT growth | -23.7% | -40.8% | 152.9% | 200.6% | -3423.1% | -348.1% | 785.9% | |
| EBIT margin | -630.7% | -834.9% | -1256.7% | -491.9% | -237.3% | 12.5% | | |
| Non-recurring items [+] | | 0.9 | | | 1.3 | | | |
| Asset impairment | | | | | 1.3 | | | |
| Interest expense, net [+] | | | 0.0 | | | 0.0 | | |
| Interest expense | | | 0.0 | | | | | |
| Interest income | | | | | | 0.0 | | |
| Other income (expense), net [+] | -0.3 | -0.3 | 1.3 | -0.4 | -0.2 | | | |
| Gain (loss) on foreign currency transactions | | | | -0.1 | -0.1 | | | |
| Other | 0.0 | 0.0 | 0.0 | 0.1 | -0.2 | | | |
| Pre-tax income | -9.1 | -12.7 | -18.1 | -8.1 | -4.0 | 0.1 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 28.3% | 0.0% | 0.0% |
| Net income | -9.1 | -12.7 | -18.1 | -7.8 | -3.5 | 0.1 | 0.0 | 0.0 |
| Net margin | -653.5% | -920.3% | -1168.6% | -497.6% | -321.5% | 9.0% | | |
| |
| Basic EPS [+] | ($0.11) | ($0.16) | ($0.24) | ($0.11) | ($0.05) | $0.00 | $0.00 | $0.00 |
| Growth | -32.9% | -33.7% | 122.8% | 102.7% | -5001.2% | -122.2% | 739.1% | |
| Diluted EPS [+] | ($0.11) | ($0.16) | ($0.24) | ($0.11) | ($0.05) | $0.00 | $0.00 | $0.00 |
| Growth | -32.9% | -33.7% | 122.8% | 102.7% | -5001.2% | -122.2% | 739.1% | |
| |
| Shares outstanding (basic) [+] | 84.9 | 79.5 | 75.1 | 72.0 | 65.0 | 51.1 | 6.3 | 6.0 |
| Growth | 6.8% | 5.8% | 4.3% | 10.7% | 27.2% | 707.3% | 5.6% | |
| Shares outstanding (diluted) [+] | 84.9 | 79.5 | 75.1 | 72.0 | 65.0 | 51.1 | 6.3 | 6.0 |
| Growth | 6.8% | 5.8% | 4.3% | 10.7% | 27.2% | 707.3% | 5.6% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |